Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology

Sector: Healthcare

Phone: 508 767 3861

Website: phiopharma.com

Address:

11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States

DonatellosLab Nov. 8 at 5:12 PM

Picked up on some of @Invinc1ble calls lately and they’ve been 🔥 If you trade, he’s definitely worth a follow💯 $VSME $PHIO $ELBM $VVPR Queue+

0 · Reply

trader_23 Nov. 8 at 4:26 PM

$PHIO

0 · Reply

NoFooling Nov. 8 at 2:22 PM

$PHIO Merger/Acquisition is now in play: PHIO/BIG PHARMA M&A PRECURSOR KEY DATES: Sept 11: Phio Long Term Incentive Plan Amended • Director Deming granted 14,000 shares PHIO @$0. • CEO Chairman Bitterman Robert granted 250,000 shares PHIO @$0. • All other Directors & Employees granted between 14,000 to 46,000 shares PHIO @$0. Oct 31: Phio turns Director Deming loose to pursue BIG PHARMA M&A= Phio Appoints David Deming to Lead Independent Director Nov 3: Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohortfor INTASYL PH-762 Skin Cancer Trial • Exercised Warrants for $13.4 Million Gross Proceeds Nov 7: INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

0 · Reply

Astrid00 Nov. 8 at 12:54 AM

$PHIO

0 · Reply

MrTicker Nov. 7 at 10:29 PM

$PHIO New 13G filed. Form SCHEDULE 13G/A Phio Pharmaceuticals Filed by: INTRACOASTAL CAPITAL, LLC 10K WIZARD 4:28 PM ET 11/7/2025 http://archive.fast-edgar.com/20251107/A722762DL222MZ4Z282T2ZY2AGQRW222Z272 Filed on: November 7, 2025

0 · Reply

cjstocksup Nov. 7 at 9:13 PM

$PHIO 100% Tumor Clearance is why I still believe we can see $4.00 to $5.00 again soon.

1 · Reply

Rohtan Nov. 7 at 9:02 PM

$PHIO I hope it’s a good decision to buy more at 1.40 today

0 · Reply

StockSenseiTrendTraders Nov. 7 at 7:00 PM

🔥 Top 5 Winning Alerts This Week! 🔥 1️⃣ $MSPR 🚀 +81.67% 🔹 Entry Alert: 0.60 🔹 Ran To: 1.09 2️⃣ $PHIO 🚀 +61.02% 🔹 Entry Alert: 2.95 🔹 Ran To: 4.75 3️⃣ $BKYI 🚀 +58.62% 🔹 Entry Alert: 0.87 🔹 Ran To: 1.38 4️⃣ $FTEL 🚀 +53.87% 🔹 Entry Alert: 3.36 🔹 Ran To: 5.17 5️⃣ $LNAI 🚀 +42.99% 🔹 Entry Alert: 1.07 🔹 Ran To: 1.53 📊 2025 Performance Highlights ✅ Wins: 1,299 ❌ Losses: 99 🚀 Gain Potential: +67,198% ✨ Avg Gain/Winning Alert: 51.73%

0 · Reply

Zackpedia Nov. 7 at 6:00 PM

$PHIO You could’ve sold when I alerted and bought back at 1.4 now if you wanted, hit Follow and subscribe to get my alerts on time and make money

0 · Reply

GABBYGIRL Nov. 7 at 4:33 PM

$PHIO only down with pressure on spy today; both Canadian & US markets in huge sell-offs.

0 · Reply

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 7:45 AM EST - 1 day ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025, 1:40 PM EST - 5 days ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 7:45 AM EST - 5 days ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025, 10:15 AM EDT - 8 days ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 21, 2025, 7:45 AM EDT - 18 days ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Sep 18, 2025, 7:45 AM EDT - 7 weeks ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 3 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 3:04 PM EDT - 3 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 3 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

May 19, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 6 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 7 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 8 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 8 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 10 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 10 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 10 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 10 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 10 months ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 10 months ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 11 months ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 11 months ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 11 months ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 1 year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Sep 25, 2024, 8:00 AM EDT - 1 year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces New Chief Financial Officer

DonatellosLab Nov. 8 at 5:12 PM

Picked up on some of @Invinc1ble calls lately and they’ve been 🔥 If you trade, he’s definitely worth a follow💯 $VSME $PHIO $ELBM $VVPR Queue+

0 · Reply

trader_23 Nov. 8 at 4:26 PM

$PHIO

0 · Reply

NoFooling Nov. 8 at 2:22 PM

0 · Reply

Astrid00 Nov. 8 at 12:54 AM

$PHIO

0 · Reply

MrTicker Nov. 7 at 10:29 PM

0 · Reply

cjstocksup Nov. 7 at 9:13 PM

$PHIO 100% Tumor Clearance is why I still believe we can see $4.00 to $5.00 again soon.

1 · Reply

Rohtan Nov. 7 at 9:02 PM

$PHIO I hope it’s a good decision to buy more at 1.40 today

0 · Reply

StockSenseiTrendTraders Nov. 7 at 7:00 PM

0 · Reply

Zackpedia Nov. 7 at 6:00 PM

$PHIO You could’ve sold when I alerted and bought back at 1.4 now if you wanted, hit Follow and subscribe to get my alerts on time and make money

0 · Reply

GABBYGIRL Nov. 7 at 4:33 PM

$PHIO only down with pressure on spy today; both Canadian & US markets in huge sell-offs.

0 · Reply

RetiredOldGeezer Nov. 7 at 4:30 PM

$PHIO Is it normal to be presenting results and not submit any updates to clinical trial government site - last update was July?

0 · Reply

Treechain Nov. 7 at 4:26 PM

$PHIO volume has dried up on way down we are owned by bagholders . But the drug is worth billions . Hold

0 · Reply

maurizio58 Nov. 7 at 4:08 PM

$PHIO there is pressure to bring it down even further

0 · Reply

MrTicker Nov. 7 at 3:32 PM

$PHIO https://www.newsfilecorp.com/release/273523

0 · Reply

MrTicker Nov. 7 at 3:31 PM

$PHIO Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 NEWSFILE CORP 9:30 AM ET 11/7/2025 King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp.(PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its ongoing Phase 1b clinical trial at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in National Harbor, Maryland from November 7-9, 2025.

0 · Reply

newsfile_corp Nov. 7 at 3:30 PM

https://nfne.ws/273523 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt

0 · Reply

chucktw387 Nov. 7 at 2:58 PM

$PHIO actually who is selling, the mc around 10 millions right now, big pharmacy will buy it for at least quarter billions, mark this post within a year.

0 · Reply

belgium_trader Nov. 7 at 2:45 PM

$PHIO any live orderbook?

0 · Reply

Be4real Nov. 7 at 2:23 PM

$PHIO People are smart here and know that this should be over 2.00. Way to hold strong! 💪🏼

0 · Reply

Bigmoney47 Nov. 7 at 2:07 PM

$PHIO I think today will hold between 1.50 to 1.55 not more because market worlds 📈📈📈📈

0 · Reply

deepeeenn Nov. 7 at 2:06 PM

$PHIO Warrants were recently executed, so a bit of dilution from that but also those warrant holders were given new warrants for a price of ~$2.05. So unlikely this will go above that. Otherwise good news

0 · Reply

Swayz99 Nov. 7 at 2:03 PM

11/7 WL -> Happy Friday! $BKYI (news, ww break of PM highs at open) $MTVA (also w/ news, ww over PM highs) $PHIO (backburner) Once again a very slow PM for small caps. The slowness continues but there will be a time where the momentum returns. Play safe for now and hopefully as we continue through November we start to see it return. All it takes is one. Have a great weekend! Happy Huntin’!

0 · Reply

Market Cap	8.48M
Revenue (ttm)	0.00
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,382,400
Avg Vol	3,445,398
Day's Range	N/A - N/A
Shares Out	5.73M
Stochastic %K	1%
Beta	0.96
Analysts	Sell
Price Target	$14.00